1. Design and properties of a novel radiopaque injectable apatitic calcium phosphate cement, suitable for image-guided implantation
- Author
-
Daphné Guenoun, Valérie Montouillout, Alain Walcarius, Jean-Michel Bouler, Franck Fayon, François-Xavier Lefèvre, Dominique Massiot, Jean-Claude Scimeca, Florian Boukhechba, Charlotte Mellier, Bruno Bujoli, Thomas Le Corroller, Caroline Robic, Christelle Despas, and Myriam Le Ferrec
- Subjects
Materials science ,Biocompatibility ,Radiodensity ,Composite number ,technology, industry, and agriculture ,Biomedical Engineering ,chemistry.chemical_element ,Calcium ,Microstructure ,Phosphate ,Apatite ,030218 nuclear medicine & medical imaging ,Biomaterials ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,chemistry ,visual_art ,visual_art.visual_art_medium ,Methyl methacrylate ,030217 neurology & neurosurgery ,Biomedical engineering - Abstract
An injectable purely apatitic calcium phosphate cement (CPC) was successfully combined to a water-soluble radiopaque agent (i.e., Xenetix® ), to result in an optimized composition that was found to be as satisfactory as poly(methyl methacrylate) (PMMA) formulations used for vertebroplasty, in terms of radiopacity, texture and injectability. For that purpose, the Xenetix dosage in the cement paste was optimized by injection of the radiopaque CPC in human cadaveric vertebrae under classical PMMA vertebroplasty conditions, performed by interventional radiologists familiar with this surgical procedure. When present in the cement paste up to 70 mg I mL-1 , Xenetix did not influence the injectability, cohesion, and setting time of the resulting composite. After hardening of the material, the same observation was made regarding the microstructure, mechanical strength and alpha-tricalcium phosphate to calcium deficient apatite transformation rate. Upon implantation in bone in a small animal model (rat), the biocompatibility of the Xenetix-containing CPC was evidenced. Moreover, an almost quantitative release of the contrast agent was found to occur rapidly, on the basis of in vitro static and dynamic quantitative studies simulating in vivo implantation. © 2017 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 106B: 2786-2795, 2018.
- Published
- 2017
- Full Text
- View/download PDF